Canadian Pharma Company To Market Armune Prostate Cancer Test

View Larger Image

Canadian Pharma Company To Market Armune Prostate Cancer Test

KALAMAZOO – The Apifiny blood test for prostate cancer developed by Kalamazoo-based Armune BioScience Inc. will be promoted by Quebec City, Quebec-based Aeterna Zentaris Inc. under a co-marketing agreement announced Tuesday.

Apifiny is the only cancer specific, non-PSA blood test for the detection of prostate cancer.

Under the co-marketing agreement, Aeterna will promote the test to designated medical professionals in its United States territories and will receive a commission for each test performed resulting from its targeted promotion.

To read the rest of this story, click on http://techcentury.com/2015/12/01/canadian-pharma-firm-to-market-kalamazoo-companys-prostate-cancer-test/

By Matt Roush|2015-12-04T13:28:31-05:00December 4th, 2015|ESD, Life Sciences|

About the Author: Matt Roush

Matt Roush is a freelance writer, editor, and photographer, and co-host of MITech TV with MITechNews founder and publisher Mike Brennan. He is a longtime Michigan journalist and marketing professional, having spent more than 30 years in journalism for media outlets including WWJ Newsradio 950, Crain’s Detroit Business, the Kalamazoo Gazette, and the Traverse City Record-Eagle, and over a decade in nonprofit media relations and marketing for The Engineering Society of Detroit and Lawrence Technological University.